Search for new therapeutics against HIV-1 via dual inhibition of RNase H and integrase: current status and future challenges.

Harsha Kharkwal, Banoth K Kumar, Sankaranarayanan Murugesan, Gautam Singhvi, Preeti Avasthi, Ankush Goyal, Joazaizulfazli Jamalis, Subhash Chander

Journal: Future medicinal chemistry 2021;13(3):269-286

PMID: 33399497

Abstract

Reverse transcriptase and integrase are key enzymes that play a pivotal role in HIV-1 viral maturation and replication. Reverse transcriptase consists of two active sites: RNA-dependent DNA polymerase and RNase H. The catalytic domains of integrase and RNase H share striking similarity, comprising two aspartates and one glutamate residue, also known as the catalytic DDE triad, and a Mg pair. The simultaneous inhibition of reverse transcriptase and integrase can be a rational drug discovery approach for combating the emerging drug resistance problem. In the present review, the dual inhibition of RNase H and integrase is systematically discussed, including rationality of design, journey of development, advancement and future perspective.

Address: Amity Institute of Phytomedicine & Phytochemistry, Amity University Uttar Pradesh, Noida-201313, India.; Department of Pharmacy, Birla Institute of Technology & Science Pilani, Pilani Campus, Pilani-333031, Rajasthan, India.; School of Pharmacy, Maharaja Agrasen University, Atal Sikha Kunj, Kalujhanda, Baddi, Solan-174103, Himachal Pradesh, India.; Department of Chemistry, Faculty of Science, Universiti Teknologi Malaysia, 81310 Johor Bahru, Johor, Malaysia.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.